The potential roles of the interplay between CCL3 and its receptors may be further supported by the observation that a CCR5 antagonist prevented CML development in nude mice receiving intra-bone marrow injection of BCR-ABL+ leukemia cells, when it was initiated immediately after the injection [43]. This evidence concerns the gene CCR5 and chronic myelogenous leukemia, BCR-ABL1 positive.